Scholarlink

Introduction <p>The NarxCare Overdose Risk Score (ORS) is a weighted measure of patient-specific prescription drug use. In patients undergoing primary total hip arthroplasty (THA), this study aimed to evaluate (1) the trend of the ORS from preoperative to 1-year postoperatively, and (2) the association of preoperative ORS with achievement of clinically meaningful improvements in patient reported outcome measures (PROMs), and satisfaction at 1-year.</p> Methods <p>All patients who underwent primary unilateral elective THA at a USA tertiary healthcare system from January 2016-December 2022 were eligible. Patients with incomplete PROMs or missing baseline NarxCare ORS were excluded, leading to the inclusion of 5,424 patients. Multivariable regression models were used to assess the association between ORS and 1-year PROMs, including achievement of the minimum clinically important difference (MCID) and Patient Acceptable Symptom State (PASS) for the Hip Disability and Osteoarthritis Outcome Score (HOOS) subdomain scores, as well as satisfaction.</p> Results <p>Preoperatively, 46.1% (<i>n</i> = 2501) had a NarxCare ORS of 0, 24.6% (<i>n</i> = 1336) had scores between 100 and 199, and 16.2% (<i>n</i> = 876) in the 200–299 range. After adjusting for confounding variables, a preoperative ORS of 100–199 was associated with failure to achieve MCID in HOOS Pain (OR 1.91;CI 1.32–2.77;<i>p</i> = 0.001), and HOOS JR (OR 1.54;1.10–2.15;<i>p</i> = 0.012). Preoperative ORS of 100–199 was also associated with failure to reach PASS threshold in HOOS Pain (OR 1.45;1.23–1.71;<i>p</i> &lt; 0.001), PS (OR 1.47;1.22–1.75;<i>p</i> &lt; 0.001) and JR (OR 1.26;1.08–1.49;<i>p</i> = 0.004), with the odds of failure continually increasing as the ORS increases. Patients with a preoperative ORS of 100–199 were 58% more likely to be dissatisfied at 1-year (OR 1.58;1.26–1.99;<i>p</i> &lt; 0.001) compared to prescription drug use naïve patients.</p> Conclusions <p>Increasing preoperative NarxCare ORS, a measure of prescription drug use, is inversely associated with patient perceived improvement after THA. An ORS of just 100 may significantly decrease the chances of clinically meaningful improvements in hip pain and function, as well as satisfaction at 1-year. A multidisciplinary approach is warranted to mitigate the detrimental effects of sedatives, opioids, or stimulant drug use and surgeons may use this easily accessible score to guide a patient centered discussion regarding postoperative improvements.</p> Level of evidence <p>III. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preoperative NarxCare overdose risk scores greater than 100 are associated with worse PROMs improvements and dissatisfaction after primary THA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Shujaa T. Khan,
  • Ahmed K. Emara,
  • Shlok V. Patel,
  • Khaled A. Elmenawi,
  • Alvaro Ibaseta,
  • Ignacio Pasqualini,
  • Chao Zhang,
  • Nicolas S. Piuzzi

摘要

Introduction

The NarxCare Overdose Risk Score (ORS) is a weighted measure of patient-specific prescription drug use. In patients undergoing primary total hip arthroplasty (THA), this study aimed to evaluate (1) the trend of the ORS from preoperative to 1-year postoperatively, and (2) the association of preoperative ORS with achievement of clinically meaningful improvements in patient reported outcome measures (PROMs), and satisfaction at 1-year.

Methods

All patients who underwent primary unilateral elective THA at a USA tertiary healthcare system from January 2016-December 2022 were eligible. Patients with incomplete PROMs or missing baseline NarxCare ORS were excluded, leading to the inclusion of 5,424 patients. Multivariable regression models were used to assess the association between ORS and 1-year PROMs, including achievement of the minimum clinically important difference (MCID) and Patient Acceptable Symptom State (PASS) for the Hip Disability and Osteoarthritis Outcome Score (HOOS) subdomain scores, as well as satisfaction.

Results

Preoperatively, 46.1% (n = 2501) had a NarxCare ORS of 0, 24.6% (n = 1336) had scores between 100 and 199, and 16.2% (n = 876) in the 200–299 range. After adjusting for confounding variables, a preoperative ORS of 100–199 was associated with failure to achieve MCID in HOOS Pain (OR 1.91;CI 1.32–2.77;p = 0.001), and HOOS JR (OR 1.54;1.10–2.15;p = 0.012). Preoperative ORS of 100–199 was also associated with failure to reach PASS threshold in HOOS Pain (OR 1.45;1.23–1.71;p < 0.001), PS (OR 1.47;1.22–1.75;p < 0.001) and JR (OR 1.26;1.08–1.49;p = 0.004), with the odds of failure continually increasing as the ORS increases. Patients with a preoperative ORS of 100–199 were 58% more likely to be dissatisfied at 1-year (OR 1.58;1.26–1.99;p < 0.001) compared to prescription drug use naïve patients.

Conclusions

Increasing preoperative NarxCare ORS, a measure of prescription drug use, is inversely associated with patient perceived improvement after THA. An ORS of just 100 may significantly decrease the chances of clinically meaningful improvements in hip pain and function, as well as satisfaction at 1-year. A multidisciplinary approach is warranted to mitigate the detrimental effects of sedatives, opioids, or stimulant drug use and surgeons may use this easily accessible score to guide a patient centered discussion regarding postoperative improvements.

Level of evidence

III.